RxDoctor Payments Data

Jeffrey Parsons, APRN

Family · Smith Center, KSNPI 1639720766

Payments from drug & device makers

$629in general payments, 2019–2025

Across 39 payments — averaging $16.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$224
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$97
  • Amgen$76
  • AstraZeneca$58
  • Novo Nordisk$29
  • Biohaven Pharmaceutical Holding Company Ltd.$27
  • plus $118 from 8 others

What the payments were for

  • Food & beverage$629100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$629 in reported general payments places this provider in the 60th percentile of 1,579 family providers in Kansas.

See all family providers in Kansas

Medicare billing

Part B allowed, 2024
$10,837
Medicare patients
61
Services billed
132

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban101$58,675
XareltoRivaroxaban79$43,974
MounjaroTirzepatide40$43,702
JardianceEmpagliflozin32$27,374
OzempicSemaglutide24$23,146
Trijardy XrEmpaglifloz/Linaglip/Metformin36$21,852
FarxigaDapagliflozin Propanediol33$18,772
Nurtec OdtRimegepant Sulfate13$12,775
Synjardy XrEmpagliflozin/Metformin Hcl19$11,636
RybelsusSemaglutide12$11,583
Bydureon BciseExenatide Microspheres13$10,580
TradjentaLinagliptin20$10,325
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$7,762
GlyxambiEmpagliflozin/Linagliptin11$6,561
Humalog Kwikpen U-100Insulin Lispro25$4,091

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Trijardy Xr, Synjardy Xr, Tradjenta, Glyxambi$16$77,747118 claims
PfizerEliquis, Nurtec Odt$14$71,449114 claims
Lilly USA, LLCMounjaro$17$43,70240 claims
Novo NordiskOzempic, Rybelsus$29$34,72936 claims
AstraZenecaFarxiga$58$18,77233 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,579 family providers in Kansas.

Other family in Smith Center

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →